HC Wainwright Raises Aura Biosciences (NASDAQ:AURA) Price Target to $22.00

Aura Biosciences (NASDAQ:AURA) had its price objective increased by HC Wainwright from $21.00 to $22.00 in a research report report published on Friday morning, Marketbeat.com reports. HC Wainwright currently has a buy rating on the stock.

A number of other research firms also recently issued reports on AURA. Evercore ISI upgraded Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Finally, JMP Securities raised their price target on Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Friday, September 13th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Aura Biosciences presently has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Trading Up 14.1 %

Shares of AURA opened at $11.74 on Friday. The business’s fifty day simple moving average is $8.66 and its two-hundred day simple moving average is $8.06. Aura Biosciences has a 12 month low of $5.99 and a 12 month high of $12.38. The company has a market cap of $581.63 million, a price-to-earnings ratio of -6.31 and a beta of 0.37.

Aura Biosciences (NASDAQ:AURA) last issued its earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.04. As a group, research analysts forecast that Aura Biosciences will post -1.7 EPS for the current year.

Insider Activity at Aura Biosciences

In related news, insider Los Pinos Elisabet De sold 24,992 shares of Aura Biosciences stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.04, for a total transaction of $300,903.68. Following the transaction, the insider now directly owns 329,847 shares in the company, valued at approximately $3,971,357.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now directly owns 121,132 shares of the company’s stock, valued at $1,193,150.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Los Pinos Elisabet De sold 24,992 shares of the firm’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $12.04, for a total value of $300,903.68. Following the sale, the insider now directly owns 329,847 shares in the company, valued at approximately $3,971,357.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aura Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. American Century Companies Inc. bought a new stake in Aura Biosciences during the second quarter valued at about $119,000. American International Group Inc. raised its holdings in Aura Biosciences by 27.4% during the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after acquiring an additional 3,782 shares during the period. Virtu Financial LLC bought a new stake in Aura Biosciences during the first quarter valued at about $144,000. SG Americas Securities LLC bought a new stake in Aura Biosciences during the third quarter valued at about $169,000. Finally, Rhumbline Advisers raised its holdings in Aura Biosciences by 39.6% during the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after acquiring an additional 18,011 shares during the period. 96.75% of the stock is owned by institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.